<DOC>
	<DOCNO>NCT00376480</DOCNO>
	<brief_summary>RATIONALE : Giving total-body irradiation chemotherapy , thiotepa fludarabine , donor stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving methylprednisolone antithymocyte globulin transplant peripheral blood cell treat laboratory transplant may stop happen . PURPOSE : This phase I trial study side effect best dose laboratory-treated peripheral blood cell infusion donor stem cell transplant treat patient hematologic cancer disease .</brief_summary>
	<brief_title>Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant Treating Patients With Hematologic Cancers Other Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish feasibility delay infusion ex vivo anergized donor peripheral blood mononuclear cell ( PBMC ) CD34-selected megadose haploidentical hematopoietic stem cell transplantation ( HSCT ) patient hematopoietic cancer disease . - Determine feasibility collect parental allogeneic stimulator cell induce anergy nonshared donor-recipient haplotype patient . - Determine feasibility collect donor PBMC source T cell ex vivo anergization . - Determine number transplant individual meet criterion proceed delayed infusion ex vivo anergized donor PBMC . - Establish safety delay infusion ex vivo anergized donor PBMC establish maximum number donor T cell infuse without unacceptable graft-versus-host disease . Secondary - Evaluate , vitro , induction specificity alloantigen hyporesponsiveness donor PBMC ex vivo anergization . - Assess , vitro , function immune cell engraft patient . - Assess , vitro , whether alloantigen hyporesponsive donor T cell present patient . - Develop , preliminarily , vitro data extent pathogen-specific immunity rate recovery . - Describe pattern opportunistic infection patient . OUTLINE : This multicenter , dose-escalation study ex vivo anergized allogeneic peripheral blood mononuclear cell ( PBMC ) . Patients treat dose level except dose level 1 stratify accord age ( 17 [ pediatric ] v 17 [ adult ] ) . - Myeloablative conditioning regimen : Patients undergo total-body irradiation twice daily day -11 -9 . Patients also receive thiotepa IV 4 hour day -8 -7 , fludarabine phosphate IV 30 minute day -7 -3 , anti-thymocyte globulin IV 8 hour methylprednisolone IV 15-30 minute day -6 -3 . - Allogeneic peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo CD34-selected PBSCT day 0 . - Ex vivo anergized allogeneic PBMC infusion : If cell engraft patient free active uncontrolled infection graft-vs-host disease , patient undergo allogeneic autologous PBMC infusion day 35 42 . Cohorts 3-8 patient receive escalate dos ex vivo anergized allogeneic PBMCs maximum tolerate dose ( MTD ) determine . The MTD define dose 2 5 3 8 patient experience dose-limiting toxicity . After completion study , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute lymphocytic leukemia In ≥ second complete remission ( CR ) , define &lt; 5 % blast bone marrow ( BM ) active extramedullary disease OR first CR follow high risk feature : History induction failure Philadelphia chromosome positive ( 4 ; 11 ) cytogenetic analysis Any infant MLL rearrangements cytogenetic analysis No relapse isolate extramedullary disease completion prior treatment Acute myeloid leukemia Failed induction therapy &lt; 3 course In ≥ second CR , define &lt; 5 % blast BM active extramedullary disease OR first CR follow highrisk feature : History induction failure = 5q monosomy 7 cytogenetic finding Any follow myelodysplastic syndrome : Refractory anemia ( RA ) excess blast ( RAEB ) high International Prognostic Scoring System ( IPSS ) score score intermediate1 ( INT1 ) intermediate2 ( INT2 ) RAEB transformation INT1 , INT2 , high IPSS score RA INT2 score Patients must healthy , related donor least genotypically HLAA , B , C , DR haploidentical patient No suitably match family donor define genotypic phenotypic identity ≥ 5/6 A , B , DR loci No immediately available genotypically match ( 6/6 ) unrelated marrow donor No immediately available umbilical cord blood donor suitable cell dose search ≥ 2 month Patients whose medical condition high risk deteriorate whose disease high risk progression donor search eligible Has parent haplotype disparate donor haplotype share patient parent , share patient donor OR patient able donate sufficient autologous cell peripheral blood draw unstimulated leukapheresis No active CNS disease PATIENT CHARACTERISTICS : Room air O_2 saturation &gt; 95 % unless lung involve disease No clinical evidence pulmonary insufficiency unless lung involve disease AST ALT &lt; 3 time upper limit normal ( ULN ) * Bilirubin &lt; 2.0 mg/dL* Creatinine &lt; 2 time ULN OR creatinine clearance glomerular filtration rate &gt; 50 % low limit normal LVEF &gt; 45 % OR shorten fraction &gt; 20 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection , define absence infectious diagnosis ( patient recent positive infectious diagnosis ) resolution fever , documentation negative culture antigen test , continuation completion course appropriate therapy , presence stable resolve clinical symptom No evidence HIV infection OR know HIV positivity NOTE : *Does apply liver involved disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior stem cell transplantation No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>